Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (CARM)
NASDAQ:CARM
Total Valuation
Carisma Therapeutics has a market cap or net worth of $10.43M. The enterprise value is $2.06M.
Market Cap$10.43M
Enterprise Value$2.06M
Share Statistics
Carisma Therapeutics has 41,788,097 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,788,097
Owned by Insiders1.43%
Owned by Institutions1.72%
Financial Efficiency
Carisma Therapeutics’s return on equity (ROE) is -3.27 and return on invested capital (ROIC) is -117.40%.
Return on Equity (ROE)-3.27
Return on Assets (ROA)-0.97
Return on Invested Capital (ROIC)-117.40%
Return on Capital Employed (ROCE)-1.20
Revenue Per Employee324.33K
Profits Per Employee-1.89M
Employee Count46
Asset Turnover0.17
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Carisma Therapeutics is -1.13. Carisma Therapeutics’s PEG ratio is 0.01.
PE Ratio-1.13
PS Ratio0.00
PB Ratio3.70
Price to Fair Value3.70
Price to FCF-1.19
Price to Operating Cash Flow-1.21
PEG Ratio0.01
Income Statement
In the last 12 months, Carisma Therapeutics had revenue of 14.92M and earned -86.88M in profits. Earnings per share was -2.59.
Revenue14.92M
Gross Profit-59.21M
Operating Income-88.73M
Pretax Income-86.88M
Net Income-86.88M
EBITDA-85.89M
Earnings Per Share (EPS)-2.59
Cash Flow
In the last 12 months, operating cash flow was -67.81M and capital expenditures -672.00K, giving a free cash flow of -68.49M billion.
Operating Cash Flow-67.81M
Free Cash Flow-68.49M
Free Cash Flow per Share-1.64
Dividends & Yields
Carisma Therapeutics pays an annual dividend of $0.361, resulting in a dividend yield of ―
Dividend Per Share$0.361
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.43
52-Week Price Change-85.81%
50-Day Moving Average0.31
200-Day Moving Average0.69
Relative Strength Index (RSI)44.23
Average Volume (3m)264.73K
Important Dates
Carisma Therapeutics upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateApr 8, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend DateMar 08, 2023
Financial Position
Carisma Therapeutics as a current ratio of 5.06, with Debt / Equity ratio of -29.81%
Current Ratio5.06
Quick Ratio5.06
Debt to Market Cap0.00
Net Debt to EBITDA0.87
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Carisma Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Carisma Therapeutics EV to EBITDA ratio is -0.28, with an EV/FCF ratio of -0.29.
EV to Sales1.59
EV to EBITDA-0.28
EV to Free Cash Flow-0.29
EV to Operating Cash Flow-0.29
Balance Sheet
Carisma Therapeutics has $26.88M in cash and marketable securities with $4.52M in debt, giving a net cash position of -$23.56M billion.
Cash & Marketable Securities$26.88M
Total Debt$4.52M
Net Cash-$23.56M
Net Cash Per Share-$0.56
Tangible Book Value Per Share$0.79
Margins
Gross margin is 80.11%, with operating margin of -594.75%, and net profit margin of -582.34%.
Gross Margin80.11%
Operating Margin-594.75%
Pretax Margin-582.34%
Net Profit Margin-582.34%
EBITDA Margin-575.74%
EBIT Margin-594.75%
Analyst Forecast
The average price target for Carisma Therapeutics is $1.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.00
Price Target Upside354.55% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast31.59%
EPS Growth Forecast57.94%